Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension.
作者信息
Zamanian Roham T, Weatherald Jason, Sweatt Andrew J, Hemnes Anna, Rashid Moira, Psotka Mitchell A, Bogaard Harm J, de Jesus Perez Vinicio
机构信息
Division of Pulmonary, Allergy and Critical Care Medicine and.
Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, California.
出版信息
Am J Respir Crit Care Med. 2024 May 15;209(10):1189-1195. doi: 10.1164/rccm.202401-0089PP.
Abstract
摘要
相似文献
1
Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2024 May 15;209(10):1189-1195. doi: 10.1164/rccm.202401-0089PP.
2
What Is Pulmonary Hypertension?
Am J Respir Crit Care Med. 2021 Mar 1;203(5):P12-P13. doi: 10.1164/rccm.2035P12.
3
Understanding the estrogen paradox of pulmonary arterial hypertension in the context of right ventricular function.
Am J Physiol Heart Circ Physiol. 2024 Aug 1;327(2):H349-H350. doi: 10.1152/ajpheart.00400.2024. Epub 2024 Jun 21.
4
The role of the exercise physiology laboratory in disease management: pulmonary arterial hypertension.
J Bras Pneumol. 2024 Sep 27;50(4):e20240240. doi: 10.36416/1806-3756/e20240240.
5
Risk Assessment in Pulmonary Arterial Hypertension.
Circ J. 2024 Sep 25;88(10):1618-1619. doi: 10.1253/circj.CJ-24-0195. Epub 2024 Mar 30.
6
Treatments for pulmonary arterial hypertension: navigating through a network of choices.
Eur Heart J. 2024 Jun 1;45(21):1953-1955. doi: 10.1093/eurheartj/ehae106.
7
The pathophysiological approach: the best for phenotyping patients with pulmonary arterial hypertension.
Clin Res Cardiol. 2024 Aug;113(8):1276-1277. doi: 10.1007/s00392-024-02479-2. Epub 2024 Jun 25.
8
Pulmonary congestion in patients with pulmonary arterial hypertension? New insights from lung ultrasound.
Eur J Heart Fail. 2024 Apr;26(4):825-828. doi: 10.1002/ejhf.3259. Epub 2024 Apr 28.
9
Could pulmonary arterial hypertension-specific agents be an option for Takayasu's arteritis related pulmonary hypertension?
Clin Exp Rheumatol. 2024 Apr;42(4):940-941. doi: 10.55563/clinexprheumatol/03vsp0. Epub 2023 Jul 5.
10
Right ventriculo-arterial coupling assessed by right ventricular strain is a superior predictor of clinical outcome in patients with pulmonary arterial hypertension.
Eur Heart J Cardiovasc Imaging. 2023 Feb 17;24(3):e53. doi: 10.1093/ehjci/jeac266.
引用本文的文献
1
Flow Cytometric Determination of Circulating Progenitor Cells in Patients With Pulmonary Arterial Hypertension: A Systematic Review.
Pulm Circ. 2025 Mar 20;15(1):e70065. doi: 10.1002/pul2.70065. eCollection 2025 Jan.
2
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study.
Am J Respir Crit Care Med. 2025 Jun;211(6):1018-1027. doi: 10.1164/rccm.202410-1929OC.
3
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01205-2024. Print 2024 Oct.
本文引用的文献
1
The Ethics of Research on Treatment Discontinuation.
NEJM Evid. 2022 Aug;1(8):EVIDe2200132. doi: 10.1056/EVIDe2200132. Epub 2022 Jul 26.
2
Automated CT-Based Quantification of Pulmonary Veins Shows Greater Central Venous Dilation in Group 2 Pulmonary Hypertension Compared With Group 1 Pulmonary Arterial Hypertension and Control Subjects.
CHEST Pulm. 2023 Dec;1(3). doi: 10.1016/j.chpulm.2023.100020. Epub 2023 Sep 9.
3
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
4
Priorities for pulmonary hypertension research: A James Lind Alliance priority setting partnership.
J Heart Lung Transplant. 2023 Jan;42(1):1-6. doi: 10.1016/j.healun.2022.09.015. Epub 2022 Oct 3.
5
The evolution of survival of pulmonary arterial hypertension over 15 years.
Pulm Circ. 2022 Oct 1;12(4):e12137. doi: 10.1002/pul2.12137. eCollection 2022 Oct.
6
Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.
Circ Res. 2022 Apr 29;130(9):1423-1444. doi: 10.1161/CIRCRESAHA.121.319969. Epub 2022 Apr 28.
7
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.
Lupus Sci Med. 2022 Mar;9(1). doi: 10.1136/lupus-2021-000634.
8
Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism.
Circ Cardiovasc Imaging. 2021 Sep;14(9):e012347. doi: 10.1161/CIRCIMAGING.120.012347. Epub 2021 Sep 21.
9
Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging.
Chest. 2021 Dec;160(6):2220-2231. doi: 10.1016/j.chest.2021.06.069. Epub 2021 Jul 13.
10
Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency.
Chest. 2021 Oct;160(4):1442-1458. doi: 10.1016/j.chest.2021.06.028. Epub 2021 Jun 26.
Zotero 插件